Forecasting the cytokine storm following systematic interleukin (IL)-2 administration

Monica C. Panelli, Richard White, Mareva Foster, Brian Martin, Ena Wang, Kina Smith, Francesco M. Marincola

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 % of patients. Since IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by a direct modulation of immune cell effector functions or through the mediation of soluble factors released as a result of IL-2 administration. We previously observed that transcriptional and protein changes induced by systemic IL-2 administration affect predominantly mononuclear phagocytes with little effect, particularly within the tumor microenvironment, on T cell activation, localization and proliferation. It further appeared that mononuclear phagocyte activation could be best explained by the indirect mediation of a secondary release of cytokines by IL-2 responsive cells either in the circulation or in peripheral tissues.

Original languageEnglish
Article number17
JournalJournal of Translational Medicine
Volume2
DOIs
Publication statusPublished - 2 Jun 2004
Externally publishedYes

Fingerprint

Interleukin-2
Cytokines
Phagocytes
Chemical activation
Tumor Microenvironment
T-cells
Renal Cell Carcinoma
Tumors
Neoplasms
Modulation
Tissue
Neoplasm Metastasis
T-Lymphocytes
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Forecasting the cytokine storm following systematic interleukin (IL)-2 administration. / Panelli, Monica C.; White, Richard; Foster, Mareva; Martin, Brian; Wang, Ena; Smith, Kina; Marincola, Francesco M.

In: Journal of Translational Medicine, Vol. 2, 17, 02.06.2004.

Research output: Contribution to journalArticle

Panelli, Monica C. ; White, Richard ; Foster, Mareva ; Martin, Brian ; Wang, Ena ; Smith, Kina ; Marincola, Francesco M. / Forecasting the cytokine storm following systematic interleukin (IL)-2 administration. In: Journal of Translational Medicine. 2004 ; Vol. 2.
@article{6d6de4ed8d1c4d4e83b7fca777d8fe4f,
title = "Forecasting the cytokine storm following systematic interleukin (IL)-2 administration",
abstract = "Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 {\%} of patients. Since IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by a direct modulation of immune cell effector functions or through the mediation of soluble factors released as a result of IL-2 administration. We previously observed that transcriptional and protein changes induced by systemic IL-2 administration affect predominantly mononuclear phagocytes with little effect, particularly within the tumor microenvironment, on T cell activation, localization and proliferation. It further appeared that mononuclear phagocyte activation could be best explained by the indirect mediation of a secondary release of cytokines by IL-2 responsive cells either in the circulation or in peripheral tissues.",
author = "Panelli, {Monica C.} and Richard White and Mareva Foster and Brian Martin and Ena Wang and Kina Smith and Marincola, {Francesco M.}",
year = "2004",
month = "6",
day = "2",
doi = "10.1186/1479-5876-2-17",
language = "English",
volume = "2",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Forecasting the cytokine storm following systematic interleukin (IL)-2 administration

AU - Panelli, Monica C.

AU - White, Richard

AU - Foster, Mareva

AU - Martin, Brian

AU - Wang, Ena

AU - Smith, Kina

AU - Marincola, Francesco M.

PY - 2004/6/2

Y1 - 2004/6/2

N2 - Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 % of patients. Since IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by a direct modulation of immune cell effector functions or through the mediation of soluble factors released as a result of IL-2 administration. We previously observed that transcriptional and protein changes induced by systemic IL-2 administration affect predominantly mononuclear phagocytes with little effect, particularly within the tumor microenvironment, on T cell activation, localization and proliferation. It further appeared that mononuclear phagocyte activation could be best explained by the indirect mediation of a secondary release of cytokines by IL-2 responsive cells either in the circulation or in peripheral tissues.

AB - Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 % of patients. Since IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by a direct modulation of immune cell effector functions or through the mediation of soluble factors released as a result of IL-2 administration. We previously observed that transcriptional and protein changes induced by systemic IL-2 administration affect predominantly mononuclear phagocytes with little effect, particularly within the tumor microenvironment, on T cell activation, localization and proliferation. It further appeared that mononuclear phagocyte activation could be best explained by the indirect mediation of a secondary release of cytokines by IL-2 responsive cells either in the circulation or in peripheral tissues.

UR - http://www.scopus.com/inward/record.url?scp=3242888623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242888623&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-2-17

DO - 10.1186/1479-5876-2-17

M3 - Article

VL - 2

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 17

ER -